1 TITLE: Viraemia and HIV drug resistance among people receiving dolutegravir versus

2 efavirenz-based first-line antiretroviral therapy

- 3
- 4 **Authors:** Jienchi Dorward^{1,2}, Yukteshwar Sookrajh³, Richard Lessells^{2,4}, Elliot Bulo³, Nicola
- 5 Bodley², Lavanya Singh⁴, Pravikrishnen Moodley⁵, Natasha Samsunder², Paul K. Drain^{6,7,8}, Gail
- 6 Hayward¹, Christopher C Butler¹, Nigel Garrett^{2,9}
- 7

8 Affiliations:

- 9 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of
 KwaZulu–Natal, Durban, South Africa.
- 12 3. eThekwini Municipality Health Unit, Durban, South Africa
- 13 4. KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of
- 14 KwaZulu-Natal, Durban, South Africa
- Department of Virology, University of KwaZulu-Natal and National Health Laboratory
 Service, Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa
- Department of Global Health, Schools of Medicine and Public Health, University of
 Washington, Seattle, USA.
- 19 7. Department of Medicine, School of Medicine, University of Washington, Seattle, USA.
- 20 8. Department of Epidemiology, School of Public Health, University of Washington, Seattle,
 21 USA.
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of
 KwaZulu-Natal, Durban, South Africa
- 24

25 **Corresponding Author:**

- 26 Jienchi Dorward
- 27 Nuffield Department of Primary Care Health Sciences, University of Oxford,
- 28 Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2
- 29 6GG; Email: jienchi.dorward@phc.ox.ac.uk
- 30

31 Word count: 1488/1500

- 32
- 33 **Keywords:** HIV, viral failure, viraemia, drug resistance, dolutegravir, efavirenz.
- 34
- 35

36 SUMMARY

- 37 Limited data exists to inform management of viraemia among people receiving dolutegravir-
- 38 based first-line ART in low- and middle-income countries. Among South-Africans with viraemia
- 39 ≥1000copies/mL receiving dolutegravir (n=43) and efavirenz (n=37), we found no dolutegravir
- 40 resistance, but high efavirenz resistance (66.7%). 12-week resuppression was higher with
- 41 dolutegravir (85%) versus efavirenz (38%).

42

43

44

45 INTRODUCTION

- 46 Dolutegravir, an integrase strand transfer inhibitor (INSTI), is currently being rolled out across
- 47 low and middle income countries (LMICs).¹² It has shown better effectiveness, tolerability, and
- 48 has a higher genetic barrier to drug resistance compared to previous non-nucleoside reverse
- 49 transcriptase (NNRTI)-based regimens such as efavirenz.³ People with viraemia receiving
- 50 dolutegravir may be more likely to have inconsistent adherence, than HIV drug resistance.
- 51 However, the absence of widespread HIV drug resistance testing in LMICs,⁴ makes it difficult for
- 52 clinicians to determine the cause of viraemia and manage it appropriately.
- 53 Among people receiving NNRTIs with viral failure (two consecutive viral loads [VLs] ≥1000
- 54 copies/mL, ≥3 months apart), approximately 70% have drug resistance, and therefore current
- 55 World Health Organization (WHO) guidelines recommend switching to second-line ART⁵⁶.
- 56 Current WHO guidelines for managing viraemia on first-line dolutegravir are less clear, because
- 57 there is little data from LMICs regarding dolutegravir drug resistance and subsequent VL
- 58 outcomes.
- 59 Therefore, among people with viraemia on dolutegravir and efavirenz-based first-line ART, we
- 60 aimed to compare subsequent VL trajectories and drug resistance profiles.

61 METHODS AND ANALYSIS

- 62 We used data from the POwER study, a randomised study of point-of-care VL testing among
- people with HIV viraemia receiving first-line ART. The protocol and results have been previously
 published^{7 8}.

65 Setting and participants

POwER was conducted at two public clinics in KwaZulu-Natal, South Africa, where dolutegravir 66 has been recommended for first- and second-line ART from December 2019.⁹ People with 67 68 viraemia ≥1000 copies/mL are recommended to receive enhanced adherence counselling, with a repeat three month VL. If this remains high, those receiving efavirenz are recommended to 69 switch to second-line ART, while those receiving dolutegravir should continue enhanced 70 71 adherence counselling and repeat VL testing. Eligibility criteria for POwER were being ≥18 72 years old, non-pregnant, and receiving first-line dolutegravir or efavirenz-based ART, with 73 viraemia ≥1000 copies/mL in the past six weeks and yet to receive enhanced adherence 74 counselling. Dolutegravir recipients may have been initiated on dolutegravir, or previously

75 transitioned from efavirenz.

76 Procedures

- 77 Consenting participants were enrolled, received enhanced adherence counselling,¹⁰ and were
- randomised to point-of-care or standard laboratory based VL testing after 12 weeks.
- 79 Management of these VL results and clinical care during the 24 weeks of follow-up was
- 80 provided by public sector healthcare workers. Plasma samples were stored at enrolment, 12
- 81 week VL and 24 week study exit visits, for retrospective VL and drug resistance testing, with
- 82 results not used for clinical management. All samples with VL ≥500 copies/mL were sequenced
- using next-generation sequencing with the Illumina MiSeq platform (Illumina, San Diego, CA)
- 84 (see supplementary material). We identified drug resistance mutations (DRM) at >20%
- 85 frequency in protease, integrase and reverse transcriptase regions using the Stanford HIVDR
- 86 database.

87 Variables and analyses

- 88 The main exposure was dolutegravir- or efavirenz-based ART at enrolment. We conducted
- 89 descriptive analyses and used Fisher's exact test to assess the proportions in each ART group
- 90 who had viraemia ≥1000 copies/mL at enrolment, 12 weeks and 24 weeks. We also assessed
- 91 the proportions with HIV drug resistance at each timepoint, and switched to second-line ART.

92 Ethical approvals

- 93 The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC
- 94 00000836/2019) and the University of Oxford Tropical Research Ethics Committee (OxTREC
- 95 66-19) approved the study.

96 RESULTS

97 Participants

- We enrolled 80 eligible participants between August- March 2022. Median age was 38.5 years
 (interguartile range [IQR] 33-45), 58.8% were female, and median time on ART was 3.2 years
- 100 (IQR 1.0-6.0) (Table S1).
- 101 At enrolment, 37 (46.3%) had been receiving efavirenz-based first-line regimens for a median of
- 102 3.2 years (1.1-5.0), and 43 (53.7%) had been receiving dolutegravir for a median of 0.7 years
- 103 (IQR 0.5-1.1). 15/43 (34.9%) had been initiated on dolutegravir, while the other 28/43 (65.1%)
- 104 had been initiated on an efavirenz-based regimen and were subsequently transitioned to first-
- 105 line dolutegravir. The dolutegravir group had less time on ART, slightly higher incomes and

- 106 higher CD4 counts, but otherwise were similar to the efavirenz group (Table S1). All participants
- 107 were receiving tenofovir disoproxil fumarate, apart from one dolutegravir participant receiving
- 108 abacavir.

109 Viraemia and HIV drug resistance

110 Enrolment

111 The median time since the pre-enrolment VL of ≥1000 copies/mL to enrolment was around two 112 weeks (Table 1). At enrolment, the numbers with viraemia ≥1000 copies/mL had fallen to 18/43 113 (41.9%) dolutegravir participants, compared to 27/37 (73.0%) efavirenz participants (p=0.007). 114 Of the 50 participants with VLs >500 copies/mL, HIVDR testing was successful in 48 for reverse 115 transcriptase and 47 for integrase. The proportion with DRMs against either of the nucleoside 116 reverse transcriptase inhibitor (NRTI) backbone drugs was lower in dolutegravir participants 117 (2/19, 10.5%, 95% CI 1.9, 32.9) compared to efavirenz participants (21/29, 72.4%, 54.0, 85.4, 118 p=<0.001, Table 1). In efavirenz participants, 25/29 (86.2%, 68.7, 95.0) had DRMs against 119 efavirenz, while among dolutegravir participants there were no DRMs against dolutegravir.

120 Follow-up

121 By the time of the 12-week VL, participants in both the dolutegravir and efavirenz group had a 122 median of 1 (IQR 1, 1) enhanced adherence counselling sessions. Only 6/43 (15.0%) of 123 dolutegravir participants had a VL ≥1000 copies/mL and were classified as having viral failure, 124 compared to 23/37 (62.2%) efavirenz participants (p<0.001). Of the 27/32 with VL >500 125 copies/mL and successful HIVDR testing, none of the dolutegravir participants had dolutegravir 126 or NRTI DRMs, compared to 19/21 (90.5%, 69.6, 98.4) efavirenz participants who had 127 resistance against the NRTI backbone (p<0.001). 21/21 (100%, 81.4, 100) had resistance 128 against efavirenz. All 23 efavirenz participants with confirmed viral failure at 12 weeks, and one 129 other with a repeat VL of 937 copies/mL, were switched to second-line regimens (Tables 1 and 130 S2), at a median of 90 days (IQR 84, 99) weeks after enrolment. The commonest second line 131 regimen was zidovudine, lamivudine and dolutegravir.

- 132 At the 24-week exit visit, two participants in each group were lost to follow-up, and one
- dolutegravir participant had no exit viral load taken. Of those with exit viral loads, viraemia was
- 134 detected in 6/40 (15.0%) of those who were receiving dolutegravir at enrolment, versus 2/35
- 135 (5.7%) of those who were receiving efavirenz at enrolment (p=0.271). Among the 8/10 with
- 136 successful NRTI HIVDR testing, 1/5 (20.0%, 2.5, 64.1) in the dolutegravir enrolment group had
- resistance against the NRTI backbone versus 3/3 (100%, 40.0, 100) in the efavirenz enrolment

138 group. One participant who was receiving TLD from enrolment, and had only NNRTI DRMs at

139 enrolment, developed an emergent K65R mutation by week 24 (Table S2). There were no

140 dolutegravir DRMs detected from enrolment to study exit in any participants.

141 DISCUSSION

At enrolment and 12-week follow-up, people receiving efavirenz-based ART with viraemia had high levels of DRMs against their first-line regimen, while people receiving dolutegravir had minimal resistance. Consequently dolutegravir participants had higher levels of resuppression at 12-weeks compared to efavirenz. After switching to second-line ART, 24-week viral resuppression in efavirenz participants became similar to dolutegravir, with few DRMs in both groups.

148 Among participants receiving dolutegravir-based ART at baseline, there were no INSTI 149 mutations, meaning that viraemia was likely caused by poor adherence. Our study is one of the 150 first to report outcomes among people experiencing viraemia on first-line dolutegravir in LMICs, 151 with 85.0% achieving viral suppression <1000 copies/mL after 12 weeks. In contrast, a high 152 proportion of participants receiving efavirenz-based ART had baseline NRTI and NNRTI 153 resistance, meaning resistance was contributing to viraemia. After 12 weeks, 37.8% re-154 suppressed to <1000 copies/mL, similar to the 46.4% among people receiving NNRTI-based ART in a large systematic review.¹¹ The remaining participants only resuppressed after 155 156 switching to second-line ART. One other study compares resuppression among people with viraemia receiving dolutegravir versus efavirenz in LMICs.¹² Among people with viraemia after 157 158 initiating ART in the ADVANCE trial, resuppression was more frequent in the dolutegravir group 159 (155/247, 62.8%) compared to efavirenz (44/138, 32%, p <0.001). There was one case of 160 emergent resistance to dolutegravir.

Strengths of our study include the focus on people with viraemia while receiving dolutegravir, successful HIVDR testing in a high proportion of those with viraemia, and frequent VL testing. The small sample size meant we could not adjust for potential confounding factors that could contribute the difference in outcomes between dolutegravir and efavirenz participants. For example, people who were transitioned to dolutegravir may be better engaged in care or motivated to adhere to treatment, and therefore also more likely to resuppress. Follow-up time was short, and the median time on dolutegravir was less than a year.

Nevertheless, our findings, alongside those of the ADVANCE study, demonstrate that early in
the South African rollout, viraemia among people receiving dolutegravir is largely due to poor

- adherence, rather than drug resistance. This supports the current South African and WHO
- 171 guidelines, which do not recommend early switching to second-line ART among people
- 172 receiving dolutegravir with viraemia. The high cost of HIV drug resistance testing, and low
- 173 prevalence of drug resistance, mean that South African Guidelines only recommend drug
- 174 resistance after two years of viraemia. Further evidence is needed to determine the extent and
- 175 impact of emergent DRMs with longer term viraemia on dolutegravir. In the meantime,
- 176 managing viraemia among people receiving dolutegravir should have a renewed focus on
- 177 interventions to support adherence, rather than managing HIVDR.

178 LIST OF ABBREVIATIONS

- 179 ART antiretroviral therapy
- 180 PLHIV people living with HIV
- 181 LMIC low- and middle-income countries
- 182 UNAIDS Joint United Nations Programme on HIV/AIDS
- 183 WHO World Health Organization
- 184

185 **DECLARATIONS**

186 Competing interests

187 Cepheid provided point-of-care VL assays at no cost for use at the study site. The authors have188 no other competing interests to declare.

189

190 Funding

- 191 This work is supported by grants from the Wellcome Trust PhD Programme for Primary Care
- 192 Clinicians (216421/Z/19/Z), the University of Oxford's Research England QR Global Challenges
- 193 Research Fund (0007365) and the Africa Oxford Initiative (AfiOx-119). HIV drug resistance
- 194 testing and drug concentration testing was funded by the National Institute for Health and Care
- 195 Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at
- 196 Oxford Health NHS Foundation Trust (MIC-2016-018); GH, CCB & PJT also receive funding
- 197 from this award. The views expressed are those of the author(s) and not necessarily those of
- the NHS, the NIHR or the Department of Health and Social Care. For the purpose of open
- access, the author has applied a CC BY public copyright licence to any Author Accepted
- 200 Manuscript version arising from this submission. The University of Oxford is the study sponsor.
- 201 The funders and sponsor had no role in study design, manuscript submission, or collection,
- 202 management, analysis or interpretation of study data.

203

204 Author contributions

- JD and NG conceived the study. YS, RL, EB, PM, NS, PKD, GH and CB contributed to study
- 206 design and implementation. JD analysed the data and wrote the first draft of the manuscript. All
- authors critically reviewed and edited the manuscript and consented to final publication.

208 Acknowledgements

- 209 The authors would like to thank all participants in the study and acknowledge the work and
- 210 support of staff at the Prince Cyril Zulu Clinic, Mafakathini Clinic, eThekwini Municipality,
- 211 CAPRISA and the National Health Laboratory Services at Addington and Inkosi Albert Luthuli
- 212 Hospitals.
- 213

214 Data sharing statement

- Bona fide researchers will be able to request access to anonymised trial data by contacting the
- corresponding author.
- 217

218 **REFERENCES**

- Dorward J, Lessells R, Drain PK, et al. Dolutegravir for first-line antiretroviral therapy in lowincome and middle-income countries: uncertainties and opportunities for implementation and research. *Lancet HIV* 2018;5(7):e400-e04. doi: 10.1016/S2352-3018(18)30093-6
 [published Online First: 2018/06/10]
- 2. Vitoria M, Hill A, Ford N, et al. The transition to dolutegravir and other new antiretrovirals in
 low-income and middle-income countries: what are the issues? *AIDS* 2018;32(12):1551 61. doi: 10.1097/QAD.00000000001845 [published Online First: 2018/05/11]
- 3. Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of
 dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV
 treatment: A systematic literature review and network meta-analysis. *EClinicalMedicine* 2020;28:100573. doi: 10.1016/j.eclinm.2020.100573 [published Online First: 2020/12/10]
- 4. Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middleincome countries. *The Lancet HIV* 2018;5(10):e588-e96. doi: 10.1016/S23523018(18)30173-5
- 5. Gregson J, Tang M, Ndembi N, et al. Global epidemiology of drug resistance after failure of
 WHO recommended first-line regimens for adult HIV-1 infection: a multicentre
 retrospective cohort study. *The Lancet Infectious Diseases* 2016;16(5):565-75. doi:
 10.1016/S1473-3099(15)00536-8
- 6. Hunt GM, Dokubo EK, Takuva S, et al. Rates of virological suppression and drug resistance
 in adult HIV-1-positive patients attending primary healthcare facilities in South Africa. *Journal of Antimicrobial Chemotherapy* 2017;72:3141-48. doi: 10.1093/jac/dkx252
- 7. Dorward J, Sookrajh Y, Ngobese H, et al. Protocol for a randomised feasibility study of Point Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POWER
 study. *BMJ Open* 2021;11(2):e045373. doi: 10.1136/bmjopen-2020-045373
- 8. Dorward J, Sookrajh Y, Lessells RJ, et al. Point-of-care viral load testing to manage HIV
 viraemia during the rollout of dolutegravir-based ART in South Africa: a randomised
 feasibility study (POwER) *Journal of Acquired Immune Deficiency Syndromes* 2023
- 9. The South African National Department of H. 2019 ART Clinical Guidelines for the
 management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates.
 Pretoria, South Africa, 2019.
- South African National Department of Health. Adherence Guidelines for HIV, TB and NCDs:
 Updated March 2020 Pretoria, South Africa2020 [Available from: <u>https://www.knowledgehub.org.za/elibrary/adherence-guidelines-hiv-tb-and-ncds-</u>
 standard-operating-procedures-2020.
- 11. Ford N, Orrell C, Shubber Z, et al. HIV viral resuppression following an elevated viral load: a
 systematic review and meta-analysis. *Journal of the International AIDS Society* 2019;22(11):1-6. doi: 10.1002/jia2.25415
- Pepperrell T, Venter WDF, McCann K, et al. Participants on Dolutegravir Resuppress
 Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. *Clin Infect Dis* 2021;73(4):e1008-e10. doi: 10.1093/cid/ciab086
- 259

260

261 **TABLES**

Table 1: Outcomes among patients with viraemia on dolutegravir and efavirenz based

263 first-line ART

| Variable | Levels | Dolutegravir, n = 43 | Efavirenz, n = 37* | р |
|-----------------------------------------------------------------------------|---------------------------------------|-------------------------|------------------------|--------|
| ENROLMENT | | | | |
| Days since pre-enrolment viral load ≥1000 copies/mL | Median (IQR) | 16.0 (13.5 to 20.0) | 14.0 (13.0 to 21.0) | 0.333 |
| Enrolment viral load, copies/mL | <1000 copies/mL | 25 (58.1) | 10 (27.0) | 0.007 |
| | ≥1000 copies/mL | 18 (41.9) | 27 (73.0) | |
| Predicted active NRTIs in current regimen [†] | 0 | 1 (5.3) | 12 (41.4) | <0.001 |
| | 1 | 1 (5.3) | 9 (31.0) | |
| | 2 | 17 (89.5) | 8 (27.6) | |
| Predicted active dolutegravir or efavirenz in current regimen [†] | No | 0 (0.0) | 25 (86.2) | <0.001 |
| | Yes | 18 (100.0) | 4 (13.8) | |
| WEEK 12 FOLLOW-UP | | | | |
| Time to follow-up viral load, days | Median (IQR) | 91.0 (84.0 to 98.0) | 90.5 (84.0 to 98.0) | 0.613 |
| Follow-up viral load, copies/mL [‡] | <1000 copies/mL | 34 (85.0) | 14 (37.8) | <0.001 |
| | ≥1000 copies/mL | 6 (15.0) | 23 (62.2) | |
| Predicted active NRTIs in current regimen§ | 0 | 0 (0.0) | 13 (61.9) | <0.001 |
| | 1 | 0 (0.0) | 6 (28.6) | |
| | 2 | 6 (100.0) | 2 (9.5) | |
| Predicted active dolutegravir or efavirenz in current regimen $\$$ | No | 0 (0.0) | 21 (100.0) | |
| | Yes | 6 (100.0) | 0 (0.0) | |
| ART regimen change during follow-up? | No | 43 (100.0) | 6 (16.2) | <0.001 |
| | Yes | | 31 (83.8) | |
| Reason for ART regimen change | ART policy change | | 7 (22.6) | 1.000 |
| | Virological failure | | 24 (77.4) [□] | |
| New ART regimen | AZT / 3TC / DTG | | 17 (54.8) | 1.000 |
| | AZT / 3TC / LPVr | | 2 (6.5) | |
| | TDF / 3TC / DTG | | 7 (22.6) | |
| | TDF / AZT / 3TC / DTG [¶] | | 4 (12.9) | |
| | TDF / FTC / LPVr | | 1 (3.2) | |
| | WEEK 24 EXIT | | | |
| Exit viral load, copies/mL** | <1000 copies/mL | 34 (85.0) | 33 (94.3) | 0.271 |
| | ≥1000 copies/mL | 6 (15.0) | 2 (5.7) | |
| Predicted active NRTIs in current regimen ^{††} | 0 | 1 (20.0) | 2 (66.7) | |
| | 1 | 0 (0.0) | 1 (33.3) | |
| | 2 | 4 (80.0) | 0 (0.0) | |
| Predicted active dolutegravir or efavirenz in current regimen ^{††} | No | 0 (0.0) | 0 (0.0) | |
| | Yes | 7 (100.0) | 3 (100.0) | |

264

* One participant had been transitioned from TDF / FTC / EFV to TDF / 3TC / DTG 15 days before enrolment, on the

same day of the pre-enrolment viral load. At the enrolment visit, they were changed back to TDF / FTC / EFV

because they should not have been transitioned while viraemic >1000 copies/mL. Their 12-week follow-up viral load

267 was 1222 copies/mL, and so they were switched from TDF/FTC/EFV to second-line AZT/3TC/LPVr

- ¹50 participants had viral load >500 copies/mL and HIVDR testing was successful in 48 for reverse transcriptase and
- 269 47 for integrase
- 270 [‡]Three participants in the dolutegravir group had no follow-up viral load
- 271 § 32 participants had viral load >500 copies/mL and HIVDR testing was successful in 27 for both reverse transcriptase
- 272 and integrase
- 273 ^{One} Participant with repeat viral load of 937 copies/mL was deemed by the clinician to have virological failure and
- 274 switched to second line AZT/3TC/DTG
- 275 [¶]Remained on tenofovir due to Hepatitis B infection
- 276 ** Two participants in each group were lost to follow-up, and one dolutegravir participant had no exit viral load
- 277 ^{t†} 10 participants had viral load >500 copies/mL and HIVDR testing was successful in 8 for reverse transcriptase and
- 278 10 for integrase